Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Medtronic AEDs in UK device alert:

This article was originally published in Clinica

Executive Summary

Problems with the energy discharge levels of some models of Medtronic's Lifepak 12 automatic external defibrillator have led the UK's Medicines and Healthcare products Regulatory Agency (MHRA) to post a device alert. The problem affects Adaptiv biphasic (and not monophasic) devices that have undergone software reinstallation or upgrade. This may have resulted in inadvertently resetting the device's output level to a default setting of 125 joules, instead of between 200 and 360 joules. Under the lower setting, which is below the Resuscitation Council UK guidelines, there is a greater risk of unsuccessful defibrillation. The National Defibrillator Programme, which is about to complete the installation of 3,000 AEDs in public places, no longer uses Medtronic's defibrillators, opting instead for Cardiac Science's Powerheart G3 AED (see this issue, p X).

You may also be interested in...

Warning Letter Close-Outs – November 2020

The US Food and Drug Administration posted two device-related closeout letters in November.

Jazz And PharmaMar’s Zepzelca Hits Buffers In ATLANTIS Study

Jazz and PharmaMar need to see what further data will be needed to convert their FDA authorization into a full approval following disappointing results in the ATLANTIS Phase III trial.

Experts Defend UK Agency Over Rapid Authorization Of COVID-19 Vaccine

As arguments rage over whether the UK regulator has rushed its assessment of the Pfizer/BioNTech vaccine, the European Medicines Agency explains why its conditional marketing authorization approach is taking a little longer.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts